NASDAQ: AVRAnteris Technologies Global Corp Stock
$9.31-0.19 (-2%)
Updated Jun 11, 2026
AVR Price
$9.31
Fair Value Price
-$0.87
Market Cap
$906.26M
52 Week Low
$2.85
52 Week High
$10.14
P/E
-4.17x
P/B
3.25x
P/S
291.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.85M
Earnings
-$95.30M
Gross Margin
74.3%
Operating Margin
-5,118.21%
Profit Margin
-5,148.8%
Debt to Equity
0.06
Operating Cash Flow
-$85M
Beta
1.69
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVR Overview
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
AVR
Ranked#35 of 42
Ranked#35 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.05 | A | |
| $15.29 | B | |
| $142.86 | B |
Be the first to know about important AVR news, forecast changes, insider trades & much more!
AVR News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVR ($9.31) is overvalued by 1,167.18% relative to our estimate of its Fair Value price of -$0.87 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVR ($9.31) is not significantly undervalued (1,167.18%) relative to our estimate of its Fair Value price of -$0.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVR due diligence checks available for Premium users.
Valuation
AVR fair value
Fair Value of AVR stock based on Discounted Cash Flow (DCF)
Price
$9.31
Fair Value
-$0.87
Undervalued by
1,167.18%
AVR ($9.31) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVR ($9.31) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.17x
Industry
42.49x
Market
13.95x
AVR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.25x
Industry
3.2x
AVR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVR's financial health
Profit margin
Revenue
$494.0k
Net Income
-$23.0M
Profit Margin
-4,660.7%
AVR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AVR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$294.7M
Liabilities
$16.3M
Debt to equity
0.06
AVR's short-term assets ($286.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVR's short-term assets ($286.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.7M
Investing
-$182.0k
Financing
$299.5M
AVR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVR vs Medical Stocks
Anteris Technologies Global Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.